The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types
(2024) In BMC Cancer 24. p.1-16- Abstract
BACKGROUND: Programmed death-ligand 1 (PD-L1) expression on tumor cells is associated with poor prognosis in several malignancies, while partly contradictory and inconclusive results have been presented for colorectal cancer (CRC). This study aimed to evaluate PD-L1 as a prognostic biomarker in CRC by comparing three different antibody clones.
METHODS: Patients surgically treated for CRC between January 1st, 2007, and December 31st, 2015, in Kalmar County, Sweden, were retrospectively included. Tissue microarrays from 862 primary tumors without neoadjuvant treatment were assessed for immunohistochemical expression of PD-L1 in tumor cells (TC) and immune cells (IC) using clones 73-10, SP263, and 22C3. Cox regression proportional... (More)
BACKGROUND: Programmed death-ligand 1 (PD-L1) expression on tumor cells is associated with poor prognosis in several malignancies, while partly contradictory and inconclusive results have been presented for colorectal cancer (CRC). This study aimed to evaluate PD-L1 as a prognostic biomarker in CRC by comparing three different antibody clones.
METHODS: Patients surgically treated for CRC between January 1st, 2007, and December 31st, 2015, in Kalmar County, Sweden, were retrospectively included. Tissue microarrays from 862 primary tumors without neoadjuvant treatment were assessed for immunohistochemical expression of PD-L1 in tumor cells (TC) and immune cells (IC) using clones 73-10, SP263, and 22C3. Cox regression proportional hazard models were used to estimate hazard ratios for overall survival (OS) and disease-free interval (DFI) in univariable and multivariable analyses, with 1% and 5% set as cut-offs for positive expression in TC and IC respectively.
RESULTS: PD-L1 expression in TC was found in 89 (10%) cases for clone 73-10, 76 (9%) for clone SP263, and 38 (4%) for clone 22C3, while the numbers for IC were 317 (37%) cases for clone 73-10, 264 (31%) for clone SP263, and 89 (10%) for clone 22C3. PD-L1 expression in IC was associated with prolonged OS and DFI in univariable analysis for all three clones. The link to prolonged DFI remained in multivariable analysis for 73-10 and SP263, but only for 73-10 regarding OS. PD-L1 expression in TC was not prognostic of OS in any analysis, while it was associated with prolonged DFI for SP263, and a trend was seen for 73-10. The link to prolonged DFI remained for SP263 and was strengthened for 73-10 in multivariable analysis.
CONCLUSIONS: The prognostic value of PD-L1 expression in both IC and TC differs between antibody clones, with 73-10 and SP263 being more reliable for prognostic information than 22C3 in resected CRC.
(Less)
- author
- Nobin, Hampus
LU
; Garvin, Stina
; Hagman, Helga
LU
; Nodin, Björn
LU
; Jirström, Karin
LU
and Brunnström, Hans LU
- organization
- publishing date
- 2024-08-26
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Humans, Colorectal Neoplasms/pathology, B7-H1 Antigen/metabolism, Male, Female, Prognosis, Aged, Middle Aged, Retrospective Studies, Biomarkers, Tumor/metabolism, Aged, 80 and over, Neoadjuvant Therapy/methods, Antibodies, Monoclonal/therapeutic use, Adult
- in
- BMC Cancer
- volume
- 24
- article number
- 1051
- pages
- 1 - 16
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:39187798
- ISSN
- 1471-2407
- DOI
- 10.1186/s12885-024-12812-7
- language
- English
- LU publication?
- yes
- additional info
- © 2024. The Author(s).
- id
- d9cb846b-0339-42f0-889c-fac53406f89b
- date added to LUP
- 2024-08-27 18:01:35
- date last changed
- 2024-08-28 07:05:12
@article{d9cb846b-0339-42f0-889c-fac53406f89b, abstract = {{<p>BACKGROUND: Programmed death-ligand 1 (PD-L1) expression on tumor cells is associated with poor prognosis in several malignancies, while partly contradictory and inconclusive results have been presented for colorectal cancer (CRC). This study aimed to evaluate PD-L1 as a prognostic biomarker in CRC by comparing three different antibody clones.</p><p>METHODS: Patients surgically treated for CRC between January 1st, 2007, and December 31st, 2015, in Kalmar County, Sweden, were retrospectively included. Tissue microarrays from 862 primary tumors without neoadjuvant treatment were assessed for immunohistochemical expression of PD-L1 in tumor cells (TC) and immune cells (IC) using clones 73-10, SP263, and 22C3. Cox regression proportional hazard models were used to estimate hazard ratios for overall survival (OS) and disease-free interval (DFI) in univariable and multivariable analyses, with 1% and 5% set as cut-offs for positive expression in TC and IC respectively.</p><p>RESULTS: PD-L1 expression in TC was found in 89 (10%) cases for clone 73-10, 76 (9%) for clone SP263, and 38 (4%) for clone 22C3, while the numbers for IC were 317 (37%) cases for clone 73-10, 264 (31%) for clone SP263, and 89 (10%) for clone 22C3. PD-L1 expression in IC was associated with prolonged OS and DFI in univariable analysis for all three clones. The link to prolonged DFI remained in multivariable analysis for 73-10 and SP263, but only for 73-10 regarding OS. PD-L1 expression in TC was not prognostic of OS in any analysis, while it was associated with prolonged DFI for SP263, and a trend was seen for 73-10. The link to prolonged DFI remained for SP263 and was strengthened for 73-10 in multivariable analysis.</p><p>CONCLUSIONS: The prognostic value of PD-L1 expression in both IC and TC differs between antibody clones, with 73-10 and SP263 being more reliable for prognostic information than 22C3 in resected CRC.</p>}}, author = {{Nobin, Hampus and Garvin, Stina and Hagman, Helga and Nodin, Björn and Jirström, Karin and Brunnström, Hans}}, issn = {{1471-2407}}, keywords = {{Humans; Colorectal Neoplasms/pathology; B7-H1 Antigen/metabolism; Male; Female; Prognosis; Aged; Middle Aged; Retrospective Studies; Biomarkers, Tumor/metabolism; Aged, 80 and over; Neoadjuvant Therapy/methods; Antibodies, Monoclonal/therapeutic use; Adult}}, language = {{eng}}, month = {{08}}, pages = {{1--16}}, publisher = {{BioMed Central (BMC)}}, series = {{BMC Cancer}}, title = {{The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types}}, url = {{http://dx.doi.org/10.1186/s12885-024-12812-7}}, doi = {{10.1186/s12885-024-12812-7}}, volume = {{24}}, year = {{2024}}, }